<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573597</url>
  </required_header>
  <id_info>
    <org_study_id>34734</org_study_id>
    <nct_id>NCT02573597</nct_id>
  </id_info>
  <brief_title>PIEB vs CEI for Labor Analgesia: An MLAC Study</brief_title>
  <official_title>Programmed Intermittent Epidural Bolus (PIEB) Compared to Continuous Epidural Infusion (CEI) Relative Efficacy and Mechanism of Efficacy For Labor Anlagesia: A Minimal Local Analgesic Concentration (MLAC) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Utilizing a 'minimal local analgesic concentration (MLAC) study' design to first determine
      the relative potency of Programmed Intermittent Epidural Bolus (PIEB) compared to Continuous
      Epidural Infusion (CEI) and secondly to determine the mechanism to explain the potential PIEB
      efficacy advantage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women who present to Labor and Delivery for an anticipated vaginal delivery will be
      identified as potential participants based on inclusion/exclusion criteria and their desire
      for labor epidural analgesia. Once identified, interested candidates will be fully informed
      of the study procedures, have all questions answered, and informed consent obtained. Pregnant
      participants will receive a labor epidural upon the patient's request and dosed per protocol
      to adequate analgesic level.

      Patients will be randomized into 1 of 4 groups. Either group I or II in Study Part A and
      group III or IV in Study Part B in a double-blinded design. Each study part will run in
      parallel and independently.

      Each group will have a varying concentration of bupivicaine infusion; continuous or
      intermittent bolus administration. In addition each group will have continuous or
      intermittent bolus administration of sufentanil. These concentrations and forms of
      administration will be blinded to both the patient and study administrator.

      Each epidural infusion concentration and continuous or bolus administration will be
      determined to be a success or failure based on analgesic scores. The investigators' primary
      outcome will be the minimal local anesthetic concentration of the final participants in each
      respective group upon study completion.

      DATA SAFETY MONITORING PLAN will follow standard of clinical care. Any adverse events will be
      reported to the PI and necessary adjustments to the protocol will be immediately instituted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MLAC of the final participants in each respective group at study completion</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first clinician rescue analgesia request (from initial epidural dose)</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical verbal pain scores</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with labor analgesia</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>0-100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of epidural analgesia</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Labor outcome (spontaneous, assisted, cesarean)</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requests to turn epidural down or stop infusion.</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total CEI and PIEB local anesthetic and opioid use</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and total dose of clinician rescue boluses</measure>
    <time_frame>approximately 6-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor weakness</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>Straight leg lift, yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal pruritis</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>scale from from 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment for pruritus, nausea and vomiting, and hypotension</measure>
    <time_frame>approximately 6-12 hours</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal nausea/vomiting</measure>
    <time_frame>6-12 hours</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Part A Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEI bupivacaine and CEI sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PIEB bupivacaine and PIEB sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEI bupivacaine and PIEB sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PIEB bupivacaine and CEI sufentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Continuous or bolus administration</description>
    <arm_group_label>Part A Group 1</arm_group_label>
    <arm_group_label>Part A Group 2</arm_group_label>
    <arm_group_label>Part B Group 3</arm_group_label>
    <arm_group_label>Part B Group 4</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Continuous or bolus administration</description>
    <arm_group_label>Part A Group 1</arm_group_label>
    <arm_group_label>Part A Group 2</arm_group_label>
    <arm_group_label>Part B Group 3</arm_group_label>
    <arm_group_label>Part B Group 4</arm_group_label>
    <other_name>sufenta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I &amp; II, Nulliparous and Multiparous, Spontaneous/Induced/Augmented Labor, Early
             active labor (cervix &lt;5 cm (if known)), Pain (VPS) &gt; 3, 18-45 years of age

        Exclusion Criteria:

          -  &lt;37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia,
             Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined
             by chronic opiate consumption), Women who are participating in another study that will
             impact protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Carvalho, MBBCh, MDCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brendan Carvalho, MBBCh, MDCH</last_name>
    <phone>(650) 724-2614</phone>
    <email>bcarvalho@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ed Riley, MD</last_name>
    <phone>(650) 723-6411</phone>
    <email>edriley@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aramina Aksamit, RN</last_name>
      <phone>512-287-0594</phone>
      <email>aramina.a@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>George RB, Allen TK, Habib AS. Intermittent epidural bolus compared with continuous epidural infusions for labor analgesia: a systematic review and meta-analysis. Anesth Analg. 2013 Jan;116(1):133-44. doi: 10.1213/ANE.0b013e3182713b26. Epub 2012 Dec 7. Review. Erratum in: Anesth Analg. 2013 Jun;116(6):1385.</citation>
    <PMID>23223119</PMID>
  </reference>
  <reference>
    <citation>Ginosar Y, Columb MO, Cohen SE, Mirikatani E, Tingle MS, Ratner EF, Angst MS, Riley ET. The site of action of epidural fentanyl infusions in the presence of local anesthetics: a minimum local analgesic concentration infusion study in nulliparous labor. Anesth Analg. 2003 Nov;97(5):1439-45.</citation>
    <PMID>14570662</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Brendan Carvalho</investigator_full_name>
    <investigator_title>Chief, Division of Obstetric Anesthesia Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

